Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1874964 | 0.84 | CA2 (0.45) | DRD3MTNR1AALOX5CA2 | |
| SCHEMBL1874689 | 0.83 | DRD2 (0.37) | DRD2DRD3CHRM1DRD4HSD11B1 | |
| SCHEMBL6938761 | 0.79 | MAOB (0.47) | DRD2DRD3CHRM1DRD4HTR1D | |
| SCHEMBL1878665 | 0.77 | MTNR1A (0.51) | MTNR1AFFAR1 | |
| SCHEMBL16339767 | 0.77 | DRD2 (0.42) | DRD2DRD3CHRM1DRD4HSD11B1 | |
| SCHEMBL25351239 | 0.75 | MTNR1A (0.39) | MTNR1AFFAR1ALOX5 | |
| SCHEMBL31550590 | 0.75 | MTNR1A (0.39) | MTNR1AFFAR1ALOX5 | |
| SCHEMBL21270524 | 0.75 | CA2 (0.38) | DRD2DRD3CHRM1DRD4HSD11B1 | |
| SCHEMBL21270522 | 0.75 | CA2 (0.38) | DRD2DRD3CHRM1DRD4HSD11B1 | |
| SCHEMBL21178299 | 0.75 | PPARG (0.38) | DRD2DRD3HSD11B1HTR1DFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | DRD2 4/4885DRD3 20/4885CHRM1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.